...
首页> 外文期刊>Nanotechnology >Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes
【24h】

Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes

机译:新型双靶紫杉醇脂质体的抗肿瘤作用增强

获取原文
获取原文并翻译 | 示例

摘要

A novel dual-targeted peptide containing an alpha V integrins specific ligand and a neuropilin-1 specific motif was developed which showed an increased specific targeting affinity to tumors. Active dual-targeted liposomes were then produced with this peptide and exhibited greater binding activity than single-targeted liposomes in vitro. Paclitaxel entrapped in this formulation greatly increased the uptake of paclitaxel in the targeting cells and significantly suppressed the growth of HUVEC and A549 cells compared with general paclitaxel injections (Taxol) and single-targeted paclitaxel liposomes. The treatment of tumor xenograft models with dual-targeted paclitaxel liposomes also resulted in better tumor growth inhibition than any other treatment groups. Therefore, the dual-targeted paclitaxel liposomes prepared in the present study might be a more promising drug for cancer treatment. Furthermore, the dual-targeting approach may produce synergistic effects that can be applied in the development of new targeted drug delivery systems.
机译:开发了一种新型的双重靶向肽,其包含αV整联蛋白特异性配体和Neuropilin-1特异性基序,显示出对肿瘤的特异性靶向亲和力增加。然后用该肽产生活性的双靶脂质体,并在体外显示出比单靶脂质体更大的结合活性。与一般的紫杉醇注射液(Taxol)和单靶紫杉醇脂质体相比,包埋在该制剂中的紫杉醇极大地增加了靶向细胞中紫杉醇的摄取,并显着抑制了HUVEC和A549细胞的生长。用双靶紫杉醇脂质体治疗肿瘤异种移植模型也比任何其他治疗组产生更好的肿瘤生长抑制作用。因此,本研究中制备的双靶紫杉醇脂质体可能是治疗癌症的更有前途的药物。此外,双重靶向方法可能产生协同效应,该协同效应可用于开发新的靶向药物递送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号